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Abstract 
Amniotic fluid (AF) obtained 
isoforms of cellular fibronectin 
from second trimester pregnancies presented extradomain (ED) A, B and an oncofetal (onc-f) domain containing 
(cFn) in Western blotting of gelatin-bound polypeptides and directly of AF. Western blotting after sequential 
immunoprecipitation suggested at least three Fn molecules: one containing EDA and the onc-f domain and another minor component distinctly 
containing all the domains, and a third one only containing EDA. The immunoblotting results for EDA-cFn and one-f-cFn were closely similar to 
that for total Fn, whereas in plasma samples of normal and pregnant women only traces of EDA-cFn and one-f-cFn, but no EDB-cFn, were found. 
Western blotting of AF also indicated the presence of three isoforms of tenascin (Tn), IV, 190,000 and 280,000 polypeptides earlier found in many 
cells, and a M, 200,000 polypeptide, novel for AF and not present in plasma. The results suggest a novel extracellular matrix polypeptide composition 
for AF. 
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1. Introduction 2. Materials and methods 
Fibronectins (Fn’s) are a family of high molecular 
weight glycoproteins present in extracellular matrix 
(ECM) fibrils and soluble in various body fluids which 
play a role in several biological phenomena [I]. In con- 
trast to plasma Fn, produced by hepatocytes and found 
soluble in body fluids and deposited in ECM [I], cFn’s 
contain extradomain (ED) sequences generated by dif- 
ferential splicing of single mRNA [1,2] or present a dis- 
tinct pattern of glycosylation in an one-f (oncofetal) 
isoform [3]. Among the cFn’s, EDA-cFn appears to be 
a minor component in plasma [4,5] but more distinctly 
present in bronchioalveolar lavage fluid [6] and amniotic 
fluid (AF) [7], the latter also containing one-f-cFn [S]. It 
has been proposed that AF-Fn is locally produced rather 
than derived from plasma [9,10]. Since then, distinct dif- 
ferences have been found in glycan residues of AF [I l- 
131 and placental Fn, as well as in their gelatin-binding 
properties [12,14-161 when compared to plasma Fn. Te- 
nascin is a novel ECM protein sharing sequence homol- 
ogy to Fn but presenting opposite functions [ 17,181, and 
is expressed during organogenesis and carcinogenesis 
[17-191. Here we have studied in detail the presence of 
2.1. Source and preparation of AF 
AF was derived by amniocentesis performed for prenatal chromo- 
some analysis at 15-16 weeks of gestation. AF was centrifuged at 
1,000 x g for 10 mm to separate the cells. Small quantities of the super- 
natant were used for Western blotting experiments, either directly or 
after gelatin-Sepharose (Pharmacia, Uppsala, Sweden) affinity chrom- 
atography 1201. Fresh samples of plasma were taken by routine methods 
gfrom normal and pregnant women. 
2.2. Western blotting and immunoprecipitation 
For some Western blotting experiments, AF or plasma was first 
subjected to immunoprecipitation using the MAb, DHl, to EDA-cFn 
[4] as described [21], MAb FDC-6 to one-f-cFn [8] or MAb 100EB2 for 
all isoforms of Tn [22]. SDS-PAGE was done using 6.5% slab gels under 
reducing conditions [23]. Then, the polypeptides were transferred onto 
nitrocellulose membranes [24] and either stained for protein or im- 
munostained. For the latter purpose the following MAb’s were used: 
DHl, BC-1 for EDB-cFn [25]; FDC-6, BF12 for total Fn [4]; BC-4 [26]; 
and lOOEB2 1221. For immunostaining, the membranes were first incu- 
bated overnight in 3% bovine serum albumin-phosphate buffered saline 
solution and then exposed to the MAb’s followed by the peroxidase- 
coupled second antibody (Dako, Glostrup, Denmark). 
2.3. Characterization of the A4Ab IOOEB2 
The MAb lOOEB2 was raised against Tn from spent culture medium 
of human embryonal fibroblasts as described [22]. To further character- 
ize this MAb, it was mapped by ELISA to specific domains of Tn by 
G. Briscoe and H.P. Erickson (Duke University, Durham, NC) [27]. 
For this purpose, bacterial and mammalian expression proteins corre- 
sponding to specific Tn domains [27] were coated on 96-well plastic 
dishes (Falcon) at 4°C at protein concentration of 5 &ml overnight. 
The wells were washed and hybridoma supematant containing the 
antibody to be tested was added to the wells for 2 h. The wells were 
washed and bound antibody was detected by peroxidase-conjugated 
secondary antibody against mouse IgG. 
Fn isoforms and Tn in AF by 
monoclonal antibodies (MAb’s). 
using isoform-specific 
*Corresponding author. Fax: (358) (0) 191 8499. 
The MAb 100EB2 gave a positive reaction in wells coated with 
HxB.L (the largest splice variant of human Tn) TnFnl-5 and TnFn3-5 
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(see [27] for domain nomenclature). It gave no reaction with any of the 
other expression proteins tested, including TnFnl-3. Therefore, this 
MAb binds to an epitope in the Fn-III domain number 4 or 5. 
3. Results and discussion 
3.1. Fn isoforms and Tn in plasma 
We first studied the presence of Fn isoforms in plasma 
samples taken from normal and pregnant women. Im- 
munoblotting experiments of SDS-PAGE separated 
polypeptides from gelatin-Sepharose affinity chroma- 
tography suggested that, while the amount of total Fn, 
as revealed with the MAb BF12, was high in both sam- 
ples (Fig. 1 panels A,B lane l), only traces of EDA-cFn 
(Fig. lA,B, lane 2) and, in contrast to a previous study 
[8], also one-f-cFn (Fig. lA,B, lane 3) could be detected. 
Even after excessive loading EDB-cFn was not detected 
(Fig. lA,B, lane 4). Due to a high protein concentration 
direct immunoblotting experiments of plasma samples 
were unsuccesful. Immunoprecipitation experiments of 
both plasma samples with the MAb lOOEB2 revealed a 
doublet of Tn polypeptides of M, 280,000 and 190,000 
(Fig. lA,B, lane 5). 
3.2. Fn isoforms in AF 
Immunoblotting experiments of gelatin-sepharose- 
bound polypeptides with the MAb’s to Fn isoforms re- 
vealed that in five different samples of AF, EDA (Fig. 
2A), EDB (Fig. 2B) and the one-f domain (Fig. 2C) 
containing isoforms could be detected. Although the re- 
actions between individual samples varied, the reaction 
for EDB was consistently weaker than that for other 
cFn’s. As Fn from AF has been reported to have a 
reduced affinity to gelatin [12,14,16] we also made direct 
immunoblottings of AF samples. These experiments re- 
vealed distinct reactions for total Fn (Fig. 3, lane l), 
EDA-cFn (Fig. 3, lane 2), one-f-cFn (Fig. 3, lane 3) and 
a weaker reaction for EDB-cFn (Fig. 3, lane 4). All these 
experiments how that, in contrast to plasma, cFn’s are 
a prominent part of AF Fn. 
1 2 3 4 5 
Fig. 1. Western blotting of SDS-PAGE-separated gelatin-bound 
polypeptides from plasma of pregnant (A) and normal (B) women for 
Fn with the MAb’s, BF12 for total Fn (lane l), DHl for EDA-cFn (lane 
2), FDC-6 for one-f-cFn (lane 3) and BC-1 for EDB-cFn (lane 4). 
Immunoprecipitation of both plasma samples with MAb lOOEB2 for 
all isoforms of Tn is shown in lane 5. 
Fig. 2. Western blotting of SDS-PAGE-separated gelatin-bound 
polypeptides from 5 different AF samples for EDA-cFn (A), one-f-cFn 
(B), EDB-cFn (C) and total Fn (D). 
The composition of Fn isoforms in AF was further 
investigated by immunoprecipitation experiments with 
the MAb DHl of AF subjected to Western blotting after 
SDS-PAGE. These experiments revealed that the EDA- 
cFn immunoprecipitate gave prominent reactions for 
total Fn (Fig. 4, lane l), EDA-cFn (Fig. 4, lane 2) and 
for one-f-cFn (Fig. 4, lane 3) but that for EDB-cFn was 
much weaker (Fig. 4, lane 4). On the other hand, a sim- 
ilar experiment with the MAb, BC-1, showed that EDB- 
cFn contained both EDA-cFn and the one-f-cFn epi- 
topes (not shown). Then we studied the Fn profile of AF 
after depletion of the one-f-cFn by two subsequent im- 
munoprecipitations with the MAb, FDC-6. Western 
blotting of the first precipitate revealed prominent reac- 
tions for the MAb’s, FDC-6 (Fig. 5, lane 1) and DHl 
(Fig. 5, lane 2), and a weaker reaction for the MAb, BC-1 
(Fig. 5, lane 3). The supernatant after two precipitations 
was subjected to gelatin-Sepharose and analyzed for cFn 
isoforms: one-f-cFn (Fig. 5, lane 4) and EDB-cFn (not 
shown) could no longer be demonstrated, indicating that 
Fig. 3. Western blotting of AF for Fn. Total Fn (lane l), EDA-cFn (lane 
2) one-f-cFn (lane 3) and EDB-cFn (lane 4). 
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Fig. 4. Immunoprecipitation of AF with MAb DHI for EDA-cFn and 
Western blotting of SDS-PAGE-separated polypeptides for total Fn 
(lane l), EDA-cFn (lane 2), one-f-cFn (lane 3) and EDB-cFn (lane 4). 
all one-f-cFn had been removed together with EDB-cFn. 
However, antibodies to EDA-cFn (Fig. 5, lane 5) and 
total Fn (Fig. 5, lane 6) still gave immunoreactive bands. 
These results suggest hat in AF there are three distinct 
cFn’s: a major polypeptide containing both EDA and the 
one-f domain, another minor polypeptide containing all 
three epitopes, and a third containing only EDA. Al- 
though the results do not allow quantitative evaluation 
they suggest hat the amount of pFn, lacking cFn epi- 
topes, is low in AF, while the opposite appears to be the 
case with plasma Fn. 
3.3. Tn in AF 
Immunoblotting experiments with the MAb’s to Tn 
polypeptides were also done with AF samples. MAb 
123456 
Fn 
Fig. 6. Western blotting of AF with MAb lOOEB2 to tenascin (lane 1). 
BF12 for total Fn (lane 2) and DHl for EDA-cFn (lane 3). 
lOOEB2 reacted with a polypeptide of M, 280,000 and a 
doublet of iV& 190,000 and 200,000 polypeptides (Fig. 6, 
lane 1). The same polypeptides could also be revealed 
with MAb BC-4 reacting with the amino-terminal part 
of Tn [26] and hence binding to all Tn polypeptides (not 
shown). For comparison, lanes 2 and 3 in Fig. 6 show 
reactions for total Fn and EDA-cFn in the same sample, 
respectively. Tn is a newly described ECM polypeptide 
sharing sequence homology with Fn but apparently dis- 
playing opposite functions [17]. The M, 280,000 and M, 
190,000 polypeptides appear to correspond to those by 
a variety of mesenchymal cells in vitro [21,26] and are 
also produced into the ECM of cultured amnion epithe- 
lial cells [21]. The distinct M, 200,000 Tn polypeptide 
may be a novel Tn variant and not a product of proteol- 
ysis as MAb BC-4, also detecting the polypeptide, reacts 
with the protease-susceptible amino-terminal part of the 
molecule [28,29]. 
During recent years much interest has been devoted to 
AF Fn and its properties in comparison to plasma Fn. 
While a few recent studies have suggested that EDA-cFn 
[7] and one-f-cFn [8,30] might be present in AF, the 
present results suggest hat AF contains three distinct 
locally produced cFn isoforms together with three Tn 
polypeptides. 
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Fig. 5. Immunoprecipitation of AF with MAb FDCd and Western 
blotting for one-f-cFn (lane l), EDAcFn (lane 2) and EDB-cFn (lane 
3). Western blotting of gelatin-Sepharose-bound polypeptides after the 
second immunoprecipitation with MAb FDC-6 for one-f-cFn (lane 4), 
EDA-cFn (lane 5) and total Fn (lane 6). Note the lack of reaction in 
lane 4, and detectable reactions in lanes 5 and 6. 
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